NCT00716092 - The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

November 30, 2008

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo (linagliptin)

once daily for 28 days

DRUG

Placebo (linagliptin)

once daily for 28 days

DRUG

Sitagliptin

100 mg once daily for 28 days

DRUG

Placebo (sitagliptin)

once daily for 28 days

DRUG

Placebo (sitagliptin)

once daily for 28 days

DRUG

Linagliptin

5mg once daily for 28 days

Trial Locations (3)

1218.37.49003 Boehringer Ingelheim Investigational Site, Berlin

1218.37.49002 Boehringer Ingelheim Investigational Site, Mainz

1218.37.49001 Boehringer Ingelheim Investigational Site, Neuss